Listed

Cellectis S.A.: Form 20-F for the period ended Dec 31, 2021

Filed with the SEC on Mar 3, 2022 and accepted by EDGAR at Mar 3, 2022, 17:07 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31$57.3mifrs-full:Revenue
Cost of revenue12 months2021-01-01 to 2021-12-31$31.4mifrs-full:CostOfSales
Operating income12 months2021-01-01 to 2021-12-31−$130.7mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2021-01-01 to 2021-12-31$0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2021-01-01 to 2021-12-31−$114.2mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2021-01-01 to 2021-12-31−$2.55ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2021-01-01 to 2021-12-31−$2.55ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2021-01-01 to 2021-12-31−$104.6mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$19.7mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2021-12-31$185.6mifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-12-31$225.4mifrs-full:CurrentAssets
Total assetsAt period end2021-12-31$382.1mifrs-full:Assets
Current liabilitiesAt period end2021-12-31$49.3mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2021-12-31$221.3mifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2021-12-3145,484,310 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-22-064482. Last ingested by Listed: Oct 28, 2026, 06:05 ET. Listed shows no prices and gives no investment advice.